Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension

Stroke

Volumn 30, Issue 2, 1999, Pages 299-305

  Fagerberg, Björn ^a   Gnarpe, Judy ^b   Gnarpe, Håkan ^b,c   Agewall, Stefan ^a   Wikstrand, John ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cardiovascular diseases; Cerebrovascular disorders; Chlamydia pneumoniae; Prospective studies

Indexed keywords

ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CYTOMEGALOVIRUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0032934397     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.2.299     Document Type: Article

References (36)

1. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
2. Grayston, JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992;15:757-763.
3. Gnarpe, H., Gnarpe, J. Increasing prevalence of specific antibodies to Chlamydia pneumoniae in Sweden. Lancet. 1993;341:381.
4. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman M-R, Manninen V, Mänttäri M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med. 1992;116:273-278.
5. Bruggeman CA. Cytomegalovirus and latency: an overview. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:325-333.
6. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang S-P, Szklo M. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med. 1993;95:499-504.
7. Cook PJ, Lip GYH, Zarifis J, Sagar G, Honeybourne, Wise R, Beevers DG. Elevated Chlamvdia pneumoniae antibody titers are associated with acute stroke syndromes. Circulation. 1995;92(suppl I):I-482-I-483. Abstract.
8. Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of Chlamydia pneumoniae with cerebrovascular disease. Stroke. 1996;27: 2207-2210.
9. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M. Cohort study of Cytomegalovirus infection as a risk factor for carotid intimal-media thickening, a measure of subclinical atherosclerosis. Circulation. 1996;94:922-927.
10. Agewall S, Fagerberg B, Berglund G, Andersson OK. Hedner T, Persson B, Samuelsson O, Wikstrand J. Multiple cardiovascular risk factor intervention: what could be achieved? Nutr Metab Cardiovasc Dis. 1993;3: 128-35.
11. Fagerberg B, Wikstrand J, Berglund G, Samuelsson O, Agewall S, for the Risk Factor Intervention Study Group. Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study. Am J Hypertens. 1998;11:14-22.
12. Suurküla M, Agewall S, Fagerberg B, Wendelhag I, Widgren B, Wikstrand J. Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high risk hypertensive patients. Arterioscler Thromb. 1994;14:1297-1304.
13. Suurküla M, Agewall S, Fagerberg B, Wendelhag I, Wikstrand J. Multiple risk intervention in high-risk hypertensive patients: a 3-year ultrasound study of intima-media thickness and plaques in the carotid artery. Arterioscler Thromb Vasc Biol. 1996;16:462-470.
14. Jauhianinen T, Toumi T, Leinonen M, Kark JD, Saikku P. Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations for Chlamydia pneumoniae by microimmunofluorescence test. J Clin Microbiol. 1994;32:839-840.
15. Gabriel AS, Gnarpe H, Gnarpe J, Hallander H, Nyquist O, Martinsson A. The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischemic heart disease. Eur Heart J. 1998;19:1321-1327.
16. Linnanmäki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993; 87:1130-1134.
17. Breslow NE, Day NE. Statistical methods in cancer research, vol II: the design and analysis of cohort studies. IARC Sci Publ. 1987;82:131-135.
18. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J. 1998;19:570-577.
19. Falck G, Heyman L, Gnarpe J, Gnarpe H. Chlamydia pneumoniae and chronic pharyngitis. Scand J Infect Dis. 1995;27:179-182.
20. Falck G, Gnarpe J, Gnarpe H. Persistent Chlamydia pneumoniae infection in a Swedish Family. Scand J Infect Dis. 1996;28:271-273.
21. Falck G, Engstrand I, Gad A, Gnarpe J, Gnarpe H, Laurila A. Demonstration of Chlamydia pneumoniae in patients with chronic pharyngitis. Scand J Infect Dis. 1997;29:585-589.
22. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae: coronary artery disease association. Arterioscler Thromb. 1992;12:945-947.
23. Karvonen M, Tuomilehto J, Pitkäniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol. 1994;23:1315-1321.
24. Miettinen H, Lehto S, Saikku P, Haffner SM, Rönnemaa T, Pyörälä K, Laakso M. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J. 1996;17:682-688.
25. Cook PJ, Lip GYH, Davies P, Beevers DG, Wise R, Honeybourne D. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension. 1998;31:589-594.
26. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ, Northfield TC. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311: 711-714.
27. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross sectional study. BMJ. 1997;314:1456-1457.
28. Ossewaarde JM, Vallinga C, Feskens EJM, Kromhout D. Infection with Chlamydia pneumoniae as a risk factor for coronary heart disease (the Zutphen Elderly Study). Atherosclerosis. 1005;115:813. Abstract 41.
29. Fong IW, Chui B, Viira E, Fong MW, Jang D, Mahoney J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48-52.
30. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Infection induces inflammatory changes in the aortas of rabbits. Infect Immun. 1997;65: 4382-4385.
31. Morrison DC, Cline LF. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol. 1977;118:326-329.
32. Harlan JM, Harker LA, Stricker GE, Deaver LJ. Effects of lipopolysaccharide on human endothelial cells in culture. Thromb Res. 1983;29: 15-26.
33. Libby P, Ordovas JM, Aauger KR, Robbins AH, Birinyi KK, Dinarello CA. Endotoxin and tumor necrosis factor induced interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986; 124:179-185.
34. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
35. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet. 1997;350:404-407.
36. Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis. 1998;177:209-212.